<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Treatment modalities used in CoVID-19 and CV adverse effects</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Therapy</th>
    <th align="left">Rationale in CoVID-19 patients</th>
    <th align="left">Cardiovascular adverse effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chloroquine and hydroxychloroquine</td>
    <td align="left">
     <p>1. Inhibits the viral entry through endosomal trafficking</p>
     <p>2. Immunomodulatory effect through cytokine attenuation</p>
    </td>
    <td align="left">QTc prolongation, bundle branch block, AV block, ventricular arrhythmias, Torsades de pointe</td>
   </tr>
   <tr>
    <td align="left">Lopinavir/ritonavir</td>
    <td align="left">
     <p>Lopinavir inhibits viral protease</p>
     <p>Ritonavir inhibits CYP3A metabolism, increasing the half-life of lopinavir</p>
    </td>
    <td align="left">Conduction abnormalities</td>
   </tr>
   <tr>
    <td align="left">Remdesivir</td>
    <td align="left">Viral RNA polymerase inhibitor</td>
    <td align="left">No serious cardiac adverse effects</td>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">Inhibits viral RNA and DNA replication</td>
    <td align="left">Hemolytic anemia</td>
   </tr>
   <tr>
    <td align="left">Corticosteroids</td>
    <td align="left">Anti-inflammatory</td>
    <td align="left">Electrolyte imbalance and hypertension</td>
   </tr>
   <tr>
    <td align="left">Anticytokine agents (tocilizumab)</td>
    <td align="left">Inhibits IL-6 and cytokine storm</td>
    <td align="left">Rare hypertension</td>
   </tr>
   <tr>
    <td align="left">Immunoglobulin therapy</td>
    <td align="left">Antibodies against the virus in the convalescent plasma</td>
    <td align="left">Transfusion-related acute lung injury leading to cardiopulmonary failure</td>
   </tr>
   <tr>
    <td align="left">Low-molecular-weight heparin</td>
    <td align="left">Anticoagulation</td>
    <td align="left">Bleeding in the cerebrovascular space, heparin-induced thrombocytopenia, deep vein thrombosis, and pulmonary embolism</td>
   </tr>
   <tr>
    <td align="left">Extracorporeal membrane oxygenation</td>
    <td align="left">Assisted extracorporeal circulation and physiologic gas exchange in cardiopulmonary failure</td>
    <td align="left">Distal ischemia and thrombosis</td>
   </tr>
   <tr>
    <td align="left">Mechanical ventilation</td>
    <td align="left">Assist spontaneous breathing in CoVID-19-induced ARDS</td>
    <td align="left">Decreased cardiac output, respiratory alkalosis, increased intracranial pressure</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>ARDS</italic> acute respiratory distress syndrome, 
   <italic>AV</italic> atrioventricular, 
   <italic>CYP</italic> cytochrome P450, 
   <italic>IL</italic> interleukin
  </p>
 </table-wrap-foot>
</table-wrap>
